JMP Securities reaffirmed their market outperform rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $25.00 price objective on the stock. Several other brokerages also recently commented on LRMR. Citigroup increased their price objective on Larimar Therapeutics from $4.50 to $10.00 and […]